J Antimicrob Chemoth 2009, 64(5):1062–1066 CrossRef 57 Likibi F,

J Antimicrob Chemoth 2009, 64(5):1062–1066.CrossRef 57. Likibi F, Jiang BB, Li BY: Biomimetic nanocoating promotes osteoblast cell adhesion on biomedical implants. J Mater Res 2008, 23(12):3222–3228.CrossRef 58. Easmon C, Lanyon H, Cole P: Use of lysostaphin to remove cell-adherent staphylococci during in vitro assays of phagocyte function. Br J Exp Pathol 1978, 59(4):381.PubMedPubMedCentral 59. Maurin M, Raoult D: Use of aminoglycosides in treatment of infections due to intracellular bacteria. Antimicrob Agents Chemother 2001, 45(11):2977–2986.PubMedCrossRefPubMedCentral 60. Kumar JK: Lysostaphin: an antistaphylococcal agent. Appl Microbiol Biotechnol 2008, 80(4):555–561.PubMedCrossRef

61. Heesemann J, Laufs R: Double immunofluorescence microscopic technique for accurate differentiation of extracellularly and intracellularly located bacteria in cell-culture. J Clin Microbiol 1985, 22(2):168–175.PubMedPubMedCentral 62. Agerer F, Waeckerle Tipifarnib research buy S, Hauck CR: Microscopic quantification of selleck compound bacterial invasion by a

novel antibody-independent staining method. J Microbiol Meth 2004, 59(1):23–32.CrossRef 63. Li H, Hamza T, Tidwell JE, Clovis N, Li B: Unique antimicrobial effects of platelet-rich plasma and its efficacy as a prophylaxis to prevent implant-associated spinal infection. Adv Healthcare Mater 2013, 2(9):1277–1284.CrossRef Selleckchem NU7441 64. Bass DA, Parce JW, Dechatelet LR, Szejda P, Seeds MC, Thomas M: Flow cytometric studies of oxidative product formation by neutrophils – a graded response to membrane stimulation. J Immunol 1983, 130(4):1910–1917.PubMed Competing

interests The authors declare that they have no Selleck Etoposide competing interests. Authors’ contributions TH participated in the design of the study, carried out the experiments, assisted in the data interpretation, and drafted the manuscript. BL conceived and designed the study, interpreted data, and revised the manuscript. Both authors read and approved the final manuscript. Authors’ information TH is currently a postdoctoral research associate at the Department of Microbiology and Immunology at the University of Maryland in Baltimore. BL is an Associate Professor in the Department of Orthopaedics, West Virginia University and a member of American Society for Microbiology (ASM), Orthopaedic Research Society (ORS), Society for Biomaterials (SFB), and American Chemical Society (ACS).”
“Background Mycobacterium tuberculosis, the agent of tuberculosis, is associated with greater morbidity and longer dormancy infection times in humans than any other type of bacterial illness. Approximately one third of the population worldwide are infected with M. tuberculosis, which causes nearly two million deaths each year [1]. The chronic state and dormancy of tuberculosis implies that M. tuberculosis has developed sophisticated strategies to modify and evade the innate and adaptive immune surveillance mechanisms of humans [2]. M.

Comments are closed.